Interestingly, BET inhibitors inhibit ALDH activity by eliminating BRD4-mediated ALDH1A1 expression through the activation of SEs and related eRNAs [158], offering a theoretical basis for the clinical application of JQ1 to inhibit the growth of cisplatin-treated ovarian cancer cells in vitro and in vivo. This evidence concerns the gene ALDH1A1 and ovarian carcinoma.